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Abstract 
Background: Imported malaria cases continue to be reported in Sri Lanka, which was declared ‘malaria-free’ by 
the World Health Organization in September 2016. Chemoprophylaxis, a recommended strategy for malaria preven-
tion for visitors travelling to malaria-endemic countries from Sri Lanka is available free of charge. The strategy of pro-
viding chemoprophylaxis to visitors to a neighbouring malaria-endemic country within the perspective of a country 
that has successfully eliminated malaria but is highly receptive was assessed, taking Sri Lanka as a case in point.
Methods: The risk of a Sri Lankan national acquiring malaria during a visit to India, a malaria-endemic country, was 
calculated for the period 2008–2013. The cost of providing prophylaxis for Sri Lankan nationals travelling to India for 1, 
2 and 4 weeks was estimated for that same period.
Results: The risk of a Sri Lankan traveller to India acquiring malaria ranged from 5.25 per 100,000 travellers in 2012 to 
13.45 per 100,000 travellers in 2010. If 50% of cases were missed by the Sri Lankan healthcare system, then the risk of 
acquiring malaria in India among returning Sri Lankans would double. The 95% confidence intervals for both risks are 
small. As chloroquine is the chemoprophylactic drug recommended for travellers to India by the Anti Malaria Cam-
paign of Sri Lanka, the costs of chemoprophylaxis for travellers for a 1-, 2- and 4-weeks stay in India on average are 
US$ 41,604, 48,538 and 62,407, respectively. If all Sri Lankan travellers to India are provided with chemoprophylaxis for 
four weeks, it will comprise 0.65% of the national malaria control programme budget.
Conclusions: Based on the low risk of acquiring malaria among Sri Lankan travellers returning from India and the 
high receptivity in previously malarious areas of the country, chemoprophylaxis should not be considered a major 
strategy in the prevention of re-introduction. In areas with high receptivity, universal access to quality-assured diagno-
sis and treatment cannot be compromised at whatever cost.
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Background
The World Health Organization (WHO) declared Sri 
Lanka ‘malaria-free’ in September 2016. Imported 
malaria cases continue to be reported across the coun-
try, with 221 cases reported between 2013 and 2016; the 
last indigenous case was reported in October 2012. The 
growth of international trade and travel, ease of travel 
and a large number of migrants arriving in the country 
has accounted for imported malaria cases in Sri Lanka. 
With high receptivity and a vulnerable population, effec-
tive strategies are required to prevent re-introduction 
and re-establishment of the disease in the country.
In spite of successful elimination programmes, resur-
gence of malaria has occurred in Eastern Europe, 
Jamaica, The Bahamas [1, 2] and the Korean peninsula 
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[3, 4]. In Greece and Turkey local transmission in lim-
ited areas occurred due to importation of malaria from 
endemic countries such as Afghanistan, India and Paki-
stan [5]. WHO has indicated that programmes to pre-
vent the re-introduction of malaria should continue 
until the goal of malaria eradication, defined as the com-
plete interruption of transmission of all forms of human 
malaria throughout the world, is achieved [5]. After being 
certified as malaria-free, the challenge facing Sri Lanka is 
to maintain “malaria-free” status and to ensure that the 
parasites are not re-introduced into the country. One of 
the main strategies identified in prevention of re-intro-
duction is early diagnosis and treatment of all infections. 
Delayed diagnosis, sometimes as much as 30  days from 
onset of illness in the latter part of the elimination pro-
gramme, has been reported in Sri Lanka [6].
Most imported malaria cases reported in Sri Lanka 
have acquired the infection from the South Asian region, 
mainly India and Pakistan [6, 7]. Between 2008 and 
2014, 196 out of 366 (over 50%) imported malaria cases 
reported in the country were acquired in India. One of 
the methods for prevention of re-introduction of malaria 
adopted by the Anti-Malaria Campaign (AMC) is regu-
lar screening of high-risk populations, including security 
personnel returning from United Nations peacekeeping 
missions, at ports of entry. Working closely with local 
authorities and international partners, such as the United 
Nations High Commission for Refugees and the Interna-
tional Organization for Migration, other high-risk groups 
such as Sri Lankan refugees returning from India are also 
screened. This activity requires a well-organized network 
whereby the date and time of arrival of the returnees are 
informed to AMC. As this procedure does not preclude 
subsequent infections being detected in the screened 
population, as they might have been incubating the para-
site when screened, these persons are screened at regular 
intervals following their return to Sri Lanka.
Chemoprophylaxis against malaria is a recommended 
strategy for visitors to malaria-endemic countries from 
elimination and prevention of re-introduction settings 
[8]. Chemoprophylaxis to visitors travelling to malaria-
endemic countries is available free of charge in Sri Lanka 
at AMC Headquarters, Regional Malaria Offices and 
at ports of entry. Security personnel departing on UN 
peacekeeping missions to malaria-endemic countries are 
issued sufficient chemoprophylaxis prior to departure 
[9]. The strategy of providing chemoprophylaxis to visi-
tors to malaria-endemic countries, within the perspec-
tive of a country that has successfully eliminated malaria 
but is highly receptive was assessed, taking Sri Lanka as a 
case in point.
Methods
The number of imported malaria cases between 2008 and 
2013 was obtained from the AMC. Information regard-
ing the total number of passengers travelling to and from 
India was obtained from the Department of Immigration 
and Emigration. Currently, the AMC issues chloroquine 
for prophylaxis to visitors travelling to India. Chloro-
quine was purchased by the Medical Supplies Division 
of the Ministry of Health with each tablet (150 mg base) 
costing approximately SLR 2.00 [US$ 1–130 Sri Lanka 
Rupees (SLR)] between 2008 and 2013.
The risk of a Sri Lankan national arriving from India 
and being detected with an imported malaria infec-
tion was calculated by dividing the number of detected 
malaria cases by the number of persons who arrived from 
India, and expressing it per 100,000 travellers. The cost 
of providing prophylaxis for Sri Lankan nationals travel-
ling to India was estimated for travel periods of one, two 
and four weeks. It was assumed that two tablets of chlo-
roquine (300 mg base) should be taken one week prior to 
departure, throughout the stay abroad and for four weeks 
at weekly intervals after return.
Results
The number of Sri Lankans who travelled to and from 
India via the Bandaranaike International Airport, the 
only international airport in the country until 2014, 
is shown in Table  1. The number of imported malaria 
cases during the same period, originating from travel 
to India as reported by AMC, is described in Table  1 
as Sri Lankan and foreign nationals. The risk of acquir-
ing malaria in India among returning Sri Lankans from 
India was extremely low ranging from 13.45 in 2010 to 
5.25 in 2012, per 100,000 travellers. If 50% of cases were 
missed by the Sri Lankan healthcare system, then the risk 
of malaria among returning Sri Lankans would double. 
The 95% confidence intervals for both risks are very small 
(Table 1).
Table  2 gives the distribution of imported malaria 
infections acquired in India by species and gender from 
2008 to 2013. Most infections were due to Plasmodium 
vivax. More infections were reported in males and among 
Sri Lankan nationals compared to foreign nationals.
The AMC chemoprophylaxis policy for travellers to 
India during this period was to administer chloroquine 
as most infections imported from India were due to P. 
vivax. A person visiting India for 1 week will need to be 
issued 12 tablets (150  mg base); a person visiting India 
for 2 weeks will have to be issued 14 tablets; a person vis-
iting India for 4 weeks will have to be issued 18 tablets of 
chloroquine. The estimated costs to Sri Lanka’s AMC are 
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given in Table 3. Compared to the cost of the prevention 
of re-introduction programme in 2015, which was esti-
mated to be US$ 11.9 million, the costs of chemoprophy-
laxis to travellers to India are trivial [10]. If the malaria 
programme costs were the same as in 2015 for the period 
2008–2013, the maximum cost of chemoprophylaxis for 
travellers to India would have been US$ 77,000 in 2011, 
assuming that all travellers were provided with chemo-
prophylaxis for a period of 4  weeks. This would have 
amounted to 0.65% of the malaria control programme 
budget.
Discussion
There are a few options available for chemoprophylaxis 
against malaria. Doxycycline and atovaquone–progua-
nil have to be taken daily. Atovaquone–proguanil has 
to be started 1  day before travel, continued throughout 
the travel period and up to 7  days after return. Simi-
larly, doxycycline has to be taken daily and continued for 
4  weeks after return. Chloroquine and mefloquine have 
to be taken before travel and continued while travelling 
and taken for four weeks at weekly intervals after return 
[11]. The AMC of Sri Lanka has a policy to provide chlo-
roquine and mefloquine as chemoprophylaxis for malaria 
to travellers free of charge.
For chloroquine chemoprophylaxis to be effective, 
it has to be taken as directed, but even then there is no 
guarantee that it will prevent a malaria infection if the 
strain of the malaria parasite is resistant to the drug. 
Both vivax and falciparum infections are reported from 
all parts of India [12, 13]. Sri Lankans visit different parts 
of India; many visit the northern and eastern states of 
India for pilgrimages to sites of Buddhist interest often 
travelling through the southern states. As such, pilgrims 
and other travellers can become infected by either Plas-
modium falciparum or P. vivax. As chloroquine and sul-
fadoxine–pyrimethamine resistance is widespread in 
India [14], the alternative chemoprophylactic agent that 
can be given by the AMC is mefloquine, according to 
the national malaria treatment guidelines [15]. The cost 
of a tablet of mefloquine is approximately SLR 250, and 
would increase costs to AMC considerably. In addition, 
mefloquine is known to produce serious adverse effects 
[16, 17].
Compliance to chemoprophylaxis has always been a 
challenge to health systems. People do not always com-
ply, not only because they forget to take the drug but also 
because of adverse events [9, 18, 19]. Even if all Sri Lan-
kan nationals who travelled to India were given chemo-
prophylaxis, it is unlikely that all will comply. In spite 
of the drugs being issued free of charge by AMC Head-
quarters, and the presence of sign boards at all regional 
malaria offices, ports of entry, and the departure lounge 
at Colombo International Airport notifying the availabil-
ity of chemoprophylaxis for travellers to malaria-endemic 
countries, the number of Sri Lankan nationals issued 
malaria prophylaxis during the period 2008–2013 was 
fewer than 5000, indicating a very poor uptake [20]. The 
AMC has developed advocacy material for the general 
public regarding the threat of re-introduction of malaria. 
Programmes and articles related to malaria are con-
ducted and displayed in the electronic and print media.
Sri Lanka has just been certified as malaria-free by 
WHO and is in the prevention of re-introduction phase. 
Previously malaria-endemic areas in the dry and inter-
mediate zones of the country are still highly receptive 
for malaria with an abundant prevalence of the principal 
vector of malaria in the past, Anopheles culicifacies. The 
climatic and ecological conditions are ideal for malaria 
transmission. Although Sri Lanka is an island, it is sur-
rounded by malarious countries, some of which have 
drug-resistant strains. With the end of the separatist war 
in 2009, tourism is thriving with a steadily increasing 
number of visitors arriving in the country each year.
Over 75% of malaria cases in the past 3 years have been 
detected by passive case detection. Passive case detec-
tion is a major strategy for detecting malaria infections 
in the prevention of re-introduction phase. Even though 
Table 1 Risk of malaria among travellers from India
Year Number of Sri Lan-
kan travellers
Number of imported malaria 
cases acquired in India among








Risk of a malaria 
infection if 50% 
of cases are missed 
(per 100,000  
travellers)
95% confidence 
interval of risk if 50% 
of cases are missed




2008 171,490 180,641 14 0 7.75 3.69–11.81 15.50 9.76–21.24
2009 175,839 181,505 15 1 8.26 4.08–12.45 16.53 10.61–22.44
2010 222,876 230,433 31 11 13.45 8.72–18.19 26.91 20.21–33.60
2011 277,856 287,155 25 11 8.71 5.29–12.12 17.41 12.59–22.24
2012 263,104 266,577 14 13 5.25 2.50–8.00 10.50 6.61–14.39
2013 240,975 243,279 27 9 11.1 6.91–15.28 22.20 16.28–28.12
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there is no indigenous malaria transmission in the coun-
try, the AMC cannot dismantle the existing passive case 
detection surveillance system. Tourism is being promoted 
by the government and the number of foreign nationals 
arriving in Sri Lanka has been increasing steadily; some 
are permanent residents of malaria-endemic countries 
while others have transited via malaria-endemic coun-
tries. In such circumstances, it is important that the 
structure and services of AMC be continued while condi-
tions are conducive for malaria transmission. Sri Lanka 
learned a bitter lesson in the past after recording 17 cases 
of malaria, of which only six cases were indigenous, in 
1963 [21]. Control operations were gradually withdrawn 
due to lack of funds, among other issues, which brought a 
resurgence of malaria.
Chemoprophylaxis is a recommended strategy, in 
addition to maintaining vigilance, case detection and 
management, and ongoing vector control, in the Global 
Technical Strategy for Malaria 2016–2030 in elimina-
tion and prevention of re-introduction settings [8]. In 
a country where receptivity is high, universal access to 
malaria diagnosis and treatment cannot be compromised 
in either the elimination or the prevention of re-intro-
duction phase as is emphasized in the Global Technical 
Strategy for Malaria. Whether chemoprophylaxis is given 
or not, in highly receptive areas that are in elimination or 
prevention of re-introduction phases, the same services 
have to be carried out to ensure that there is no laxity in 
surveillance. As most imported cases in Sri Lanka, since 
the last indigenous case, have been detected by passive 
Table 2 Distribution of imported malaria infections acquired in India by species and sex 2008–2013

















2008 Male 7 0 1 0 1 0 9 0
Female 3 0 0 0 2 0 5 0
Total 10 0 1 0 3 0 14 0
2009 Male 7 1 1 0 0 0 8 1
Female 3 0 4 0 0 0 7 0
Total 10 0 5 0 0 0 15 1
2010 Male 21 9 4 1 0 1 25 11
Female 2 0 3 0 1 0 6 0
Total 23 9 7 1 1 1 31 11
2011 Male 20 11 1 0 1 0 22 0
Female 3 0 0 0 0 0 3 0
Total 23 11 1 9 1 0 25 11
2012 Male 8 13 1 0 2 0 11 13
Female 2 0 0 0 1 0 3 0
Total 10 13 1 0 3 0 14 13
2013 Male 17 9 4 0 0 0 21 9
Female 6 0 0 0 0 0 6 0
Total 23 9 4 0 0 0 27 9
Table 3 Estimated costs of chemoprophylaxis to the Anti-Malaria Campaign
a  SLR refers to Sri Lankan Rupees (1 USD ~130 SLR between 2008 and 2013)








2008 171,490 4,115,760 4,801,720 6,173,640
2009 175,839 4,220,136 4,923,492 6,330,204
2010 222,876 5,349,024 6,240,528 8,023,536
2011 277,856 6,668,544 7,779,968 10,002,816
2012 263,104 6,314,496 7,366,912 9,471,744
2013 240,975 5,783,400 6,747,300 8,675,100
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case detection, chemoprophylaxis should not be a main 
strategy for prevention of re-introduction or re-establish-
ment of malaria after malaria elimination at the expense 
of reducing passive case detection services. In elimina-
tion and prevention of re-introduction phases in highly 
receptive areas, the ultimate test for a malaria control 
programme is the response mounted when imported 
cases are reported to prevent re-establishment of malaria 
transmission.
In addition to chemoprophylaxis, the AMC recom-
mends combining chemoprophylaxis with use of per-
sonal protection measures (use of insect repellents, 
wearing clothes with long sleeves, long trousers, or using 
insecticide-treated nets). Advice regarding personal pro-
tection measures is given when chemoprophylaxis drugs 
are dispensed. The public is also advised regarding chem-
oprophylaxis and use of personal protection measures via 
mass media campaigns.
Chemoprophylaxis, provided it is effective and com-
plied with, has benefits for the recipient. If a traveller is 
visiting a country or region where the health system is 
poor, chemoprophylaxis may be life-saving. Chemopro-
phylaxis may also be useful among persons from coun-
tries where receptivity for malaria is low as physicians 
may not tend to consider malaria in the differential diag-
nosis. However, there is evidence, even from Sri Lanka 
where malaria was endemic in a large part of the country, 
that physicians have ‘forgotten’ about the possibility of 
malaria, and the time from onset of symptoms to diag-
nosis has exceeded 30 days in some cases [6]. The AMC 
provides regular updates to clinicians through profes-
sional bodies, such as the Sri Lanka Medical Association. 
The monthly newsletter of the Sri Lanka Medical Associ-
ation carries a caption indicating the number of imported 
malaria cases reported for the year as a reminder to clini-
cians of the existing threat.
A review of malaria resurgence in countries that suc-
cessfully eliminated malaria reveals that four failures 
occurred in 50 countries. Data suggest that with elimina-
tion, onward malaria transmission potential has declined 
by more than 50-fold (i.e., more than 98%) since before 
elimination [22].
The analogy that best describes the need to main-
tain quality-assured passive case detection surveillance 
system in malaria elimination and prevention of re-
introduction settings is the global polio eradication ini-
tiative. Even though wild polio virus infections have been 
reported in only three countries in 2016, polio immuni-
zation is carried out throughout the world and cannot be 
discontinued until eradication is achieved [23]. The same 
is the case for malaria in a highly receptive setting.
Conclusions
The issue of whether chemoprophylaxis for travellers vis-
iting malaria-endemic areas should be a major strategy 
in malaria elimination and prevention of re-introduction 
phases in areas with high receptivity is highlighted. Based 
on the risk of acquiring malaria among Sri Lankan trav-
ellers returning from India and the high receptivity in 
previously malarious areas of the country, chemoprophy-
laxis should not be considered as a major strategy in the 
prevention of re-introduction phase. In areas with high 
receptivity, universal access to quality-assured diagnosis 
and treatment cannot be compromised at whatever cost 
until after eradication.
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